Scarica l'app Stockscreener
0.5248
4.58%
-0.0252
Dopo l'orario di chiusura:
.52
-0.0048
-0.91%
Precedente Chiudi:
$0.55
Aprire:
$0.543
Volume 24 ore:
75,097
Relative Volume:
0.11
Capitalizzazione di mercato:
$32.42M
Reddito:
-
Utile/perdita netta:
$-68.80M
Rapporto P/E:
-0.4485
EPS:
-1.17
Flusso di cassa netto:
$-59.06M
1 W Prestazione:
-6.29%
1M Prestazione:
-14.94%
6M Prestazione:
-29.72%
1 anno Prestazione:
-57.68%
Intervallo 1D:
$0.5202
$0.565
Intervallo di 1 settimana:
$0.5202
$0.5917
Portata 52W:
$0.451
$1.79
Passage Bio Inc Stock (PASG) Company Profile
Nome
Passage Bio Inc
Settore
Industria
Telefono
(267) 866-0312
Indirizzo
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Confronta PASG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
0.5248 | 32.42M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-29 | Ripresa | Wedbush | Outperform |
| 2024-09-03 | Iniziato | Rodman & Renshaw | Buy |
| 2022-03-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-01-19 | Downgrade | Goldman | Buy → Neutral |
| 2021-07-01 | Iniziato | Raymond James | Outperform |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-03-04 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-02-04 | Iniziato | Guggenheim | Buy |
| 2021-01-25 | Iniziato | Wedbush | Outperform |
| 2021-01-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-12-11 | Iniziato | Citigroup | Neutral |
| 2020-08-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-25 | Downgrade | Goldman | Buy → Neutral |
| 2020-03-25 | Iniziato | Chardan Capital Markets | Buy |
| 2020-03-24 | Iniziato | Cowen | Outperform |
| 2020-03-24 | Iniziato | Goldman | Buy |
| 2020-03-24 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Passage Bio Inc Borsa (PASG) Ultime notizie
Layoff Tracker: Spotlight Goes Dark After Disappointing Preclinical Data for CRISPR Platform - BioSpace
Passage Bio Inc to Host Earnings Call - ACCESS Newswire
Passage Bio (NASDAQ:PASG) versus SpringWorks Therapeutics (NASDAQ:SWTX) Head to Head Review - Defense World
Passage Bio will again trim workforce in latest cost-cutting move - The Business Journals
Passage Bio CFO sells shares worth $1,685 - MSN
Fierce Biotech Layoff Tracker 2025: Encoded trims 29% of team; Inventiva halves staff - Fierce Biotech
Passage Bio CFO sells shares worth $1,685 By Investing.com - Investing.com UK
2024 Q4 Job Market Report: Biopharma Job Postings Slowed as Layoffs Continued - BioSpace
Passage Bio shares transition to Nasdaq Capital Market - MSN
Passage Bio shares transition to Nasdaq Capital Market By Investing.com - Investing.com South Africa
TELA Bio Grants Inducement Stock Units to New Employees - MyChesCo
Passage Bio Out-Licenses Rare Disease Programs to GEMMA Biotherapeutics - MSN
Annovis Bio Secures U.S. Patent for Neuroprotective Drug Buntanetap - MyChesCo
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc - GuruFocus.com
Orbimed advisors reduces stake in Passage Bio for $142,223 By Investing.com - Investing.com South Africa
Passage Bio Reports Promising Data in Trial for Frontotemporal Dementia Treatment - MSN
Orbimed advisors reduces stake in Passage Bio for $142,223 - Investing.com
Gryphon Bio, Inc. Pioneers Novel Blood Biomarker Panel to Monitor Treatment Journey for Patients with Traumatic Brain Injury and Alzheimer's - BioSpace
Passage Bio Cutting 55% of Staff to Help Extend Cash Runway - BioSpace
Geode Capital Management LLC Has $351,000 Position in Nutriband Inc. (NASDAQ:NTRB) - Defense World
Passage Bio, Inc. (NASDAQ:PASG) Shares Acquired by Geode Capital Management LLC - Defense World
Passage Bio (NASDAQ:PASG) Announces Restructuring Plan and Financial Update - Defense World
Head-To-Head Comparison: Passage Bio (NASDAQ:PASG) vs. JATT Acquisition (NYSE:JATT) - Defense World
Passage Bio Inc Azioni (PASG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):